Recent studies have revealed that MTA3 functions not only as an independent prognostic biomarker in HCC but also as a key oncogenic factor involved in tumor progression and immune modulation, highlighting its significant potential for clinical translation (39). The gene discussed is MTA3; the disease is hepatocellular carcinoma.